Companies Johnson & Johnson

Johnson & Johnson

New Brunswick, New Jersey, USA

Total Offices: 9

143,612 Total Employees

Year Founded: 1886

View Website

Jobs at Similar Companies

Similar Companies Hiring

Sailor Health

Telehealth • Social Impact • Healthtech

New York City, NY

20 Employees

Granted

Mobile • Insurance • Healthtech • Financial Services • Artificial Intelligence

New York, New York

23 Employees

Fortune Brands Innovations

Manufacturing

Deerfield, IL

2450 Employees

Johnson & Johnson Company Stability & Growth

Updated on March 04, 2026

This page summarizes recurring themes identified from responses generated by popular LLMs to common candidate questions about Johnson & Johnson and has not been reviewed or approved by Johnson & Johnson.

What's the stability & growth outlook for Johnson & Johnson?

Strengths in revenue momentum, innovation-led performance, and a two-engine pharma-plus-devices model are accompanied by headwinds from major patent/biosimilar exposure and portfolio reshaping. Together, these dynamics suggest a generally resilient growth profile, with near-term stability dependent on execution in backfilling maturing franchises and integrating recent MedTech deals.

Positive Themes About Johnson & Johnson

Strong Revenue Growth: Companywide sales are described as increasing year over year, with momentum exiting 2025 and guidance calling for continued expansion into 2026.
Innovation-Driven Growth: Growth is attributed to innovative medicines and new product submissions, with oncology and immunology performance highlighted as key contributors.
Diversified Revenue Streams: The business is positioned around two large segments—Innovative Medicine and MedTech—creating a broader platform that helps offset declines in specific products.

Considerations About Johnson & Johnson

Stagnant Product Portfolio: Patent expirations and biosimilar competition—especially around Stelara—are expected to create a meaningful step-down that needs to be backfilled by newer launches.
Strategic Drift: Ongoing portfolio reshaping, including discussion of separating orthopedics, can introduce temporary disruption to reported growth and margins as the mix is rebalanced.
Operational Inefficiency: Integrating recent MedTech acquisitions is cited as an execution priority, implying integration complexity that can weigh on near-term performance if not managed tightly.

NEW

What does AI tell candidates about your employer brand?

Get your free AI reputation report today.

See AI Report

The insights on this page are generated by submitting structured prompts to some of the most popular large language models (“LLMs”) and summarizing recurring themes from the responses. Because the insights are generated using AI, they may contain errors. The insights do not necessarily reflect internal data, employee interviews, or verified company information. They may be influenced by incomplete, outdated, or inaccurate data, and may vary across LLM providers. These insights are intended for informational purposes only and should not be interpreted as a factual or definitive assessment of a company's reputation. Built In makes no representations or warranties regarding the accuracy, completeness, or reliability of this information, and disclaims any liability for any actions taken based on this information. If you are a representative of this company, and would like this page to be removed, you may contact us via this form.